MCK · 10-Q · 2026Q2

MCKESSON CORP

Filed 2026-08-05 · Consumer · View original filing on EDGAR

Ranked Events

• Liquidity and Debt PositionImportance 84 · Surprise 74
  Cash and cash equivalents increased to $5.164 billion at June 30, 2026, from $3.975 billion at March 31, 2026, while total assets increased to $88.330 billion from $82.323 billion. Total debt increased to $9.729…
• Oncology Specialty DemandImportance 70 · Surprise 56
  Oncology & Multispecialty revenue increased 33% year over year to $14,222 million from $10,658 million in the three months ended June 30, 2026. The segment serves specialty-care markets through specialty drug…
• FX / Currency ImpactImportance 68 · Surprise 58
  McKesson operates in U.S. dollars and the functional currencies of foreign subsidiaries, including Canadian dollars, euros, and British pounds sterling, creating translation and intercompany-loan exposure. In July…
• Opioid LitigationImportance 65 · Surprise 60
  McKesson and two other national pharmaceutical distributors entered a $7.9 billion settlement with participating U.S. states, subdivisions, the District of Columbia, and eligible territories, with payments extending…
• Medical-Surgical SeparationImportance 53 · Surprise 60
  On June 1, 2026, Apollo Global Management affiliates invested approximately $1.25 billion in convertible preferred equity of Medical-Surgical Solutions for an approximately minority ownership interest classified as…
• Debt Financing and LiquidityImportance 52 · Surprise 42
  In the first quarter of fiscal 2027, subsidiaries in the Medical-Surgical Solutions segment entered into syndicated financing totaling $3.2 billion of net proceeds. The financing includes $750 million of senior secured…
• Capital Return ProgramImportance 46 · Surprise 42
  McKesson returned $2.6 billion of cash to shareholders during the three months ended June 30, 2026. Common-stock repurchases totaled $2.5 billion, including a $2.3 billion March accelerated share repurchase completed…
• Headcount and RestructuringImportance 40 · Surprise 42
  During the first quarter of fiscal 2027, McKesson approved multi-year Corporate initiatives involving organizational changes, process enhancements, and automation solutions to improve efficiency and productivity. The…
• Regulatory RiskImportance 38 · Surprise 24
  McKesson files tax returns in U.S. federal, U.S. state, and foreign jurisdictions and had $1.6 billion of unrecognized tax benefits as of June 30, 2026. Of that amount, $1.5 billion would reduce income tax expense and…
• Pharmaceutical Distribution VolumesImportance 37 · Surprise 32
  North American Pharmaceutical revenue increased $4.0 billion, or 5%, year over year to $86.8 billion. Higher volumes from institutional healthcare providers and retail national account customers were the principal…
• Market Demand TrendsImportance 37 · Surprise 32
  McKesson reported broad market growth in the three months ended June 30, 2026, led by North American Pharmaceutical demand. Growth reflected higher drug utilization, newly launched products, and higher volumes from…
• Operational Efficiency InitiativesImportance 37 · Surprise 42
  McKesson’s Prescription Technology Solutions segment launched an operational-efficiency and cost-optimization initiative to align the business with its long-term strategy. The actions include headcount reductions,…
• Income Tax Rate ChangesImportance 35 · Surprise 48
  Income tax expense increased to $276 million from $220 million for the three months ended June 30, 2026. The reported income tax rate increased to 21.1% from 20.9%, a 20-basis-point increase. The rate change was driven…
• Net Income and ProfitabilityImportance 35 · Surprise 48
  Net income attributable to McKesson declined 22% to $614 million from $784 million for the three months ended June 30, 2026. Diluted earnings per share decreased 18% to $5.15 from $6.25, despite diluted…
• Revenue Performance and MixImportance 34 · Surprise 32
  Total revenue increased 8% year over year to $105.38 billion from $97.83 billion for the three months ended June 30, 2026. North American Pharmaceutical revenue rose 5% to $86.77 billion, with U.S. sales increasing…
• Geographic Market CommentaryImportance 32 · Surprise 24
  The U.S. was the primary geographic source of North American Pharmaceutical growth. U.S. sales increased $3.7 billion, driven primarily by higher volumes from institutional healthcare providers and retail national…
• Healthcare Customer GrowthImportance 25 · Surprise 32
  Medical-Surgical Solutions revenue increased $118 million, or 4%, year over year to $2.8 billion. Sales to extended care customers rose $79 million, while sales to ambulatory care customers rose $35 million. Both…
• Recent Accounting PronouncementsImportance 25 · Surprise 42
  The FASB issued ASU 2024-03, requiring interim and annual disaggregation of certain income-statement costs and expenses; it becomes effective for McKesson fiscal years beginning after December 15, 2026, with interim…
• Operating Expense TrendsImportance 24 · Surprise 14
  Selling, distribution, general, and administrative expenses increased 3.1% year over year to $2.264 billion for the quarter ended June 30, 2026, from $2.196 billion. Total operating expenses increased 5.5% to $2.366…
• Capital ExpendituresImportance 23 · Surprise 22
  Capital expenditures for property, plant, and equipment and capitalized software were $152 million for the three months ended June 30, 2026. Capital expenditures decreased from $189 million in the prior-year period.…

Revenue by Product (in millions)